4//SEC Filing
Evoke Pharma Inc 4
Accession 0000904454-15-000536
$EVOKCIK 0001403708operating
Filed
Aug 19, 8:00 PM ET
Accepted
Aug 20, 4:59 PM ET
Size
14.6 KB
Accession
0000904454-15-000536
Insider Transaction Report
Form 4
Evoke Pharma IncEVOK
Halak Brian K
10% Owner
Transactions
- Sale
Common Stock
2015-08-18$7.02/sh−11,836$83,089→ 1,052,328 total
BLAIR JAMES C
10% Owner
Transactions
- Sale
Common Stock
2015-08-18$7.02/sh−11,836$83,089→ 1,052,328 total
DOVEY BRIAN H
10% Owner
Transactions
- Sale
Common Stock
2015-08-18$7.02/sh−11,836$83,089→ 1,052,328 total
TREU JESSE I
10% Owner
Transactions
- Sale
Common Stock
2015-08-18$7.02/sh−11,836$83,089→ 1,052,328 total
SCHOEMAKER KATHLEEN K
10% Owner
Transactions
- Sale
Common Stock
2015-08-18$7.02/sh−11,836$83,089→ 1,052,328 total
DOMAIN PARTERS VII L P
10% Owner
Transactions
- Sale
Common Stock
2015-08-18$7.02/sh−11,836$83,089→ 1,052,328 total
VITULLO NICOLE
10% Owner
Transactions
- Sale
Common Stock
2015-08-18$7.02/sh−11,836$83,089→ 1,052,328 total
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.17. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F2]The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of One Palmer Square Associates VII, LLC ("OPSA VII"), the sole general partner of the Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- [F3]As managing members of OPSA VII, which is also the sole general partner of DP VII Associates, L.P. each Reporting Owner listed below may also be deemed to indirectly beneficially own 17,947 shares of Common Stock held by DP VII Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by DP VII Associates, L.P., however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
- [F4]As managing members of Domain Associates, LLC, each Reporting Owner listed below may also be deemed to indirectly beneficially own 5,250 shares of Common Stock held by Domain Associates, LLC. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Associates, LLC, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
Documents
Issuer
Evoke Pharma Inc
CIK 0001403708
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001403708
Filing Metadata
- Form type
- 4
- Filed
- Aug 19, 8:00 PM ET
- Accepted
- Aug 20, 4:59 PM ET
- Size
- 14.6 KB